Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. INFU
INFU logo

INFU Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
9.170
Open
9.080
VWAP
8.92
Vol
135.81K
Mkt Cap
177.60M
Low
8.780
Amount
1.21M
EV/EBITDA(TTM)
7.73
Total Shares
20.18M
EV
202.00M
EV/OCF(TTM)
8.56
P/S(TTM)
1.34
InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others.
Show More

Events Timeline

(ET)
2026-05-18
16:40:00
InfuSystem Approves $20M Stock Repurchase Program
select
2026-05-07 (ET)
2026-05-07
07:30:00
Q1 Revenue at $33.7M, Below Consensus
select
2026-03-02 (ET)
2026-03-02
09:40:00
InfuSystem Trading Resumes
select
2026-03-02
09:40:00
InfuSystem Trading Halted Due to Volatility
select
2026-02-24 (ET)
2026-02-24
06:40:00
2026 Revenue Consensus at $148.06M
select
2026-02-24
06:40:00
Q4 Revenue at $36.2M, CEO Highlights Growth and Buybacks
select

News

seekingalpha
8.0
05-18seekingalpha
InfuSystem Approves $20 Million Stock Buyback Program
  • Buyback Program Initiation: InfuSystem's board has approved a stock repurchase program allowing the company to buy back up to $20 million of its common stock from July 1, 2026, to June 30, 2028, reflecting confidence in future growth prospects.
  • Positive Stock Reaction: Following the announcement, InfuSystem's shares rose over 4% in extended trading, indicating strong market confidence in the buyback program, which may further enhance investor sentiment.
  • Historical Buyback Data: Under the current authorization, as of March 31, 2026, the company has repurchased approximately 1.6 million shares for about $11.9 million, demonstrating a consistent commitment to share repurchases and effective execution.
  • Management Confidence: CEO Carrie Lachance emphasized that this buyback program not only continues the company's established repurchase policy but also showcases the company's ability to achieve profitable growth and long-term value creation, ensuring flexibility to repurchase shares when market conditions are favorable.
Newsfilter
8.0
05-18Newsfilter
InfuSystem Approves $20 Million Stock Repurchase Program
  • Stock Repurchase Program: InfuSystem's Board of Directors has approved a stock repurchase program authorizing the company to buy back up to $20 million of its common stock from July 1, 2026, to June 30, 2028, reflecting the company's confidence in future growth.
  • Previous Buyback Activity: As of March 31, 2026, InfuSystem repurchased approximately 1.6 million shares for about $11.9 million under the previous authorization, indicating a proactive approach to capital management.
  • Flexible Capital Utilization: CEO Carrie Lachance emphasized that this repurchase program not only continues the company's established buyback policy but also provides flexibility to enhance shareholder value and support long-term growth when valuations are attractive.
  • Business Model Overview: InfuSystem operates through two platforms, Patient Services and Device Solutions, covering oncology, pain management, and wound therapy, showcasing its comprehensive competitiveness in the medical equipment market.
seekingalpha
9.5
05-07seekingalpha
InfuSystem Holdings Reports Q1 2026 Earnings with Mixed Results
  • Revenue Performance: InfuSystem reported Q1 2026 revenue of $33.7 million, a decline of $1 million from the prior year, although a 1.7% increase on a pro forma basis indicates resilience amid challenges.
  • EBITDA Growth: Despite the revenue drop, adjusted EBITDA reached $6.4 million, remaining consistent with the previous year, while the EBITDA margin slightly improved to 18.9%, reflecting the company's cost control efforts.
  • Wound Care Business Growth: Wound care net revenue was $2.1 million, more than doubling year-over-year with a 112% increase, driven by approximately 60% growth from the compression device product line, highlighting strong demand and market potential.
  • ERP System Launch: The company successfully launched its new ERP system on March 1, 2026, facing initial challenges but expecting it to enhance operational efficiency and cost savings in the future, with management expressing optimism about cash flow stability.
Newsfilter
9.5
05-07Newsfilter
InfuSystem Q1 Results: Revenue Decline but Enhanced Profitability
  • Revenue Overview: InfuSystem reported net revenues of $33.7 million for Q1, a 3% decline year-over-year primarily due to the restructuring of the GE Healthcare services contract; however, on a pro forma basis, net revenue grew by 1.7%, indicating improved profitability.
  • Profitability Enhancement: Adjusted EBITDA stood at $6.4 million with an EBITDA margin of 18.9%, reflecting the company's successful strategy to reduce direct contract expenses, thereby enhancing overall economic performance despite lower revenues.
  • Wound Care Growth: The wound care segment achieved net revenues of $2.1 million in Q1, more than doubling year-over-year, with approximately 60% of this growth driven by sales of compression devices, showcasing the potential of new therapies and expanding market share.
  • ERP System Launch: The company successfully went live with its new ERP system on March 1, 2026, which is expected to improve productivity and cost visibility, optimize the utilization of medical devices, and provide a scalable platform for future growth.
Newsfilter
9.5
04-30Newsfilter
InfuSystem to Release Q1 2026 Financial Results on May 7, 2026
  • Earnings Release Schedule: InfuSystem Holdings, Inc. will issue its Q1 2026 financial results on May 7, 2026, before market open, reflecting the company's ongoing commitment to transparency and investor communication.
  • Investor Conference Call: The company will hold a conference call at 9:00 a.m. Eastern Time on the same day to discuss its financial results, enhancing engagement with investors and stakeholders.
  • Participation Details: Investors can join the call by dialing (833) 366-1127 or (412) 902-6773, or by listening via a live webcast on the company's website, demonstrating the company's emphasis on accessible communication channels.
  • Replay Information: A replay of the call will be available until May 14, 2026, allowing investors who cannot participate live to access key information, thereby ensuring comprehensive communication of financial performance.
seekingalpha
9.5
02-24seekingalpha
InfuSystem Holdings Reports Strong Q4 2025 Earnings with Strategic Growth Outlook
  • Significant Revenue Growth: InfuSystem reported net revenue of $36.2 million for Q4 2025, reflecting a 7% year-over-year increase, with Oncology and Wound Care segments growing by 2.8% and over 160% respectively, indicating strong performance in the medical device market.
  • Record Adjusted EBITDA: The adjusted EBITDA for Q4 reached $8.8 million, representing 24.3% of net revenue, marking a quarterly record that highlights the company's success in cost control and operational efficiency.
  • Optimistic Future Outlook: Management anticipates revenue growth between 6% and 8% for 2026, despite a $7.1 million revenue reduction due to contract restructuring, with new products and technology-driven efficiencies expected to support this growth.
  • Robust Cash Flow: Operating cash flow for 2025 exceeded $24.4 million, with available liquidity nearing $58 million at year-end, demonstrating the company's ongoing commitment to capital allocation and shareholder value creation.
Wall Street analysts forecast INFU stock price to rise
4 Analyst Rating
Wall Street analysts forecast INFU stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
12.00
Averages
13.67
High
15.00
Current: 0.000
sliders
Low
12.00
Averages
13.67
High
15.00
Lake Street
Ben Haynor
Buy
maintain
$15
AI Analysis
2026-02-25
Reason
Lake Street
Ben Haynor
Price Target
$15
AI Analysis
2026-02-25
maintain
Buy
Reason
Lake Street analyst Ben Haynor raised the firm's price target on InfuSystem to $17.50 from $15 and keeps a Buy rating on the shares. Although revenue fell below consensus in Q4, the firm was "pleased with the company's performance relative to our model" and trusts management to "make correct decisions leading to high ROIC," the analyst tells investors.
Roth Capital
Buy
maintain
$14 -> $15
2026-02-24
Reason
Roth Capital
Price Target
$14 -> $15
2026-02-24
maintain
Buy
Reason
Roth Capital raised the firm's price target on InfuSystem to $15 from $14 and keeps a Buy rating on the shares following "above-consensus" Q4 results. The firm cites higher forward estimates and confidence in the business for the price target bump. Roth Capital told investors in a research note that improved treatment volumes in patient services benefited the core oncology business and the wound care division while an increase in sales of medical equipment and biomedical services revenue drove growth in device solutions.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for INFU
Unlock Now

Valuation Metrics

The current forward P/E ratio for InfuSystem Holdings Inc (INFU.A) is 22.73, compared to its 5-year average forward P/E of 71.55. For a more detailed relative valuation and DCF analysis to assess InfuSystem Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
71.55
Current PE
22.73
Overvalued PE
141.53
Undervalued PE
1.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
8.98
Current EV/EBITDA
9.63
Overvalued EV/EBITDA
11.38
Undervalued EV/EBITDA
6.58

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.54
Current PS
1.14
Overvalued PS
2.14
Undervalued PS
0.93

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

can you ive me stocks to buy at around $10
Intellectia · 58 candidates
Region: USPrice: $8.00 - $12.00Relative Vol: >= 1.50Week Price Change Pct: >= $0.00One Week Rise Prob: >= 50
Ticker
Name
Market Cap$
top bottom
SUZ logo
SUZ
Suzano SA
10.11B
BCRX logo
BCRX
BioCryst Pharmaceuticals Inc
2.14B
NYC logo
NYC
American Strategic Investment Co
24.12M
CRMD logo
CRMD
CorMedix Inc
655.86M
NMR logo
NMR
Nomura Holdings Inc
24.58B
MBC logo
MBC
Masterbrand Inc
1.08B
any suggestions for day trades for Monday?
Intellectia · 44 candidates
Price: $3.00 - $100.00Price Change Pct: >= $2.50Beta: HighRiskMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
ANF logo
ANF
Abercrombie & Fitch Co
4.48B
THAR logo
THAR
Tharimmune Inc
193.30M
ACMR logo
ACMR
ACM Research Inc
3.77B
SENS logo
SENS
Senseonics Holdings Inc
299.49M
AAOI logo
AAOI
Applied Optoelectronics Inc
2.98B
WHR logo
WHR
Whirlpool Corp
4.49B

Whales Holding INFU

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is InfuSystem Holdings Inc (INFU) stock price today?

The current price of INFU is 8.8 USD — it has decreased -3.72

What is InfuSystem Holdings Inc (INFU)'s business?

InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others.

What is the price predicton of INFU Stock?

Wall Street analysts forecast INFU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INFU is13.67 USD with a low forecast of 12.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is InfuSystem Holdings Inc (INFU)'s revenue for the last quarter?

InfuSystem Holdings Inc revenue for the last quarter amounts to 33.68M USD, decreased -2.97

What is InfuSystem Holdings Inc (INFU)'s earnings per share (EPS) for the last quarter?

InfuSystem Holdings Inc. EPS for the last quarter amounts to 0.05 USD, decreased -600.00

How many employees does InfuSystem Holdings Inc (INFU). have?

InfuSystem Holdings Inc (INFU) has 461 emplpoyees as of June 18 2026.

What is InfuSystem Holdings Inc (INFU) market cap?

Today INFU has the market capitalization of 177.60M USD.